In vitro activities of hexaazatrinaphthylenes against Leishmania spp

Antimicrobial Agents and Chemotherapy
Atteneri López-ArencibiaJosé E Piñero

Abstract

The in vitro activity of a novel group of compounds, hexaazatrinaphthylene derivatives, against two species of Leishmania is described in this study. These compounds showed a significant dose-dependent inhibition effect on the proliferation of the parasites, with 50% inhibitory concentrations (IC(50)s) ranging from 1.23 to 25.05 μM against the promastigote stage and 0.5 to 0.7 μM against intracellular amastigotes. Also, a cytotoxicity assay was carried out to in order to evaluate the possible toxic effects of these compounds. Moreover, different assays were performed to determine the type of cell death induced after incubation with these compounds. The obtained results highlight the potential use of hexaazatrinaphthylene derivatives against Leishmania species, and further studies should be undertaken to establish them as novel leishmanicidal therapeutic agents.

References

Sep 1, 1993·Journal of Natural Products·K LikhitwitayawuidN Ruangrungsi
Sep 30, 2000·Clinical and Experimental Dermatology·N C Hepburn
Jan 2, 2001·Transactions of the Royal Society of Tropical Medicine and Hygiene·M BoelaertP Van der Stuyft
Jul 1, 2004·Comparative Immunology, Microbiology and Infectious Diseases·P Desjeux
Sep 24, 2004·Journal of the American Chemical Society·Xavier CrispinWilliam R Salaneck
Dec 27, 2005·Antimicrobial Agents and Chemotherapy·Karin Seifert, Simon L Croft
Jan 19, 2006·Clinical Microbiology Reviews·Simon L CroftAlan H Fairlamb
Jun 1, 2006·Advances in Parasitology·Jorge AlvarPiero Olliaro
Jan 9, 2007·Parasitology Research·María Gabriela Cabrera-SerraJosé E Piñero
Jun 26, 2007·Trends in Parasitology·Iris BruchhausVolker T Heussler
Aug 24, 2007·The Lancet Infectious Diseases·Richard ReithingerSimon Brooker
Oct 11, 2008·Cell Death and Differentiation·G KroemerUNKNOWN Nomenclature Committee on Cell Death 2009
Jul 3, 2009·Cell Cycle·Steven N HochwaldVita M Golubovskaya
Nov 4, 2009·Molecular Carcinogenesis·Donghang ZhengSteven N Hochwald
Nov 6, 2009·Journal of Biomedicine & Biotechnology·Helena C Maltezou
Jan 23, 2010·Methods in Molecular Biology·Juan Román Luque-Ortega, Luis Rivas
Feb 18, 2010·Cell Cycle·Elizabeth A BeierleVita M Golubovskaya
Sep 22, 2010·Antimicrobial Agents and Chemotherapy·Jacob Lorenzo-MoralesEnrique Martínez-Carretero
Sep 28, 2010·Current Opinion in Infectious Diseases·Piero L Olliaro
Aug 20, 2011·Organic & Biomolecular Chemistry·Daniel García VelázquezAngel Gutiérrez Ravelo
Apr 6, 2012·Vaccine·Bhawana Singh, Shyam Sundar
Feb 25, 2014·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Diego Dinis BouPatricia Sartorelli
Dec 3, 2014·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Ines SifaouiJosé E Piñero

❮ Previous
Next ❯

Citations

Apr 10, 2016·Experimental Parasitology·Atteneri López-ArencibiaJosé E Piñero
Jan 18, 2017·Antimicrobial Agents and Chemotherapy·Atteneri López-ArencibiaJosé E Piñero
May 19, 2018·Current Medicinal Chemistry·Rosa M RegueraRafael Balaña-Fouce
Jun 30, 2018·Parasitology Research·Soumaya HajajiJosé E Piñero
May 1, 2018·Journal of Enzyme Inhibition and Medicinal Chemistry·Verônica da Silva CardosoClaudiu T Supuran

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.